Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells

Blood

Volumn 119, Issue 24, 2012, Pages 5807-5816

  Mérino, Delphine ^a,b   Khaw, Seong L ^a,b,c,d   Glaser, Stefan P ^a,b   Anderson, Daniel J ^e   Belmont, Lisa D ^e   Wong, Chihunt ^e   Yue, Peng ^e   Robati, Mikara ^a   Phipson, Belinda ^a,b   Fairlie, Walter D ^a,b   Lee, Erinna F ^a,b   Campbell, Kirsteen J ^a,g   Vandenberg, Cassandra J ^a,b   Cory, Suzanne ^a,b   Roberts, Andrew W ^a,b,f   Ludlam, Mary J C ^e   Huang, David C S ^a,b   Bouillet, Philippe ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e GENENTECH INC   (United States)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; BIM PROTEIN; CELL PROTEIN; MULTIPROTEIN COMPLEX; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOID CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 84862489317     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-400929     Document Type: Article

References (50)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324-1337. (Pubitemid 46328466)
2. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell. 2000;6(6):1389-1399. (Pubitemid 32045931)
3. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275-283. (Pubitemid 46474662)
4. Bachmann PS, Piazza RG, Janes ME, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013-3022.
5. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(6):961-968. (Pubitemid 46638851)
6. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681. (Pubitemid 40825512)
7. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389-399. (Pubitemid 44711953)
8. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186. (Pubitemid 46427871)
9. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene. 2007;26(16):2374- 2380. (Pubitemid 46572819)
10. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68(7):2321-2328. (Pubitemid 351521806)
11. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
12. Wilson WH, O'Connor OA, Czuczman MS, et al. navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159.
13. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
14. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226(4678):1097-1099. (Pubitemid 15217831)
15. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121. (Pubitemid 46048458)
16. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008;111(4):2300-2309. (Pubitemid 351451437)
17. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2986-2993. (Pubitemid 27172586)
18. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci U S A. 1999;96(26):14943-14948. (Pubitemid 30019744)
19. Campbell KJ, Bath ML, Turner ML, et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood. 2010;116(17):3197-3207.
20. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538. (Pubitemid 16173038)
21. Merino D, Giam M, Hughes PD, et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol. 2009;186(3):355-362.
22. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738. (Pubitemid 129515880)
23. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science. 2003;302(5647):1036-1038. (Pubitemid 37386194)
24. Puthalakath H, Villunger A, O'Reilly LA, et al. Bmf: a pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001;293:1829-1832. (Pubitemid 32845780)
25. Huang DCS, Cory S, Strasser A. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene. 1997;14(4):405-414. (Pubitemid 27087103)
26. Lee EF, Fedorova A, Zobel K, et al. Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the prosurvival Bcl-2 proteins. J Biol Chem. 2009;284(45):31315-31326.
27. Anderson DJ, Durieux JK, Song K, et al. Live-cell microscopy reveals small molecule inhibitor effects on MAPK pathway dynamics. PLoS One. 2011;6(8):e22607.
28. Wong C, Anderson DJ, Lee EF, Fairlie WD, Ludlam MJC. Direct visualization of Bcl-2 family protein interactions using live cell fluorescent protein redistribution assays. Cell Death Disease. 2012;3:e288.
29. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67(3):1176-1183.
30. Certo M, Moore Vdel G, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351-365. (Pubitemid 43668734)
31. Al-Harbi S, Hill BT, Mazumder S, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood. 2011;118(13):3579-3590.
32. Lin X, Morgan-Lappe S, Huang X, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene. 2007;26(27):3972-3979. (Pubitemid 46884293)
33. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679. (Pubitemid 351432507)
34. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996. (Pubitemid 37087056)
35. Smith AJ, Dai H, Correia C, et al. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286(20):17682-17692.
36. Mason KD, Vandenberg CJ, Scott CL, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A. 2008;105(46):17961-17966.
37. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403. (Pubitemid 40193310)
38. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909-916.
39. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91(9):3379-3389. (Pubitemid 28193890)
40. Chen S, Dai Y, Pei XY, Grant S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009;29(23):6149-6169.
41. Jorgensen TN, McKee A, Wang M, et al. Bim and Bcl-2 mutually affect the expression of the other in T cells. J Immunol. 2007;179(6):3417-3424.
42. Wuilleme-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M. Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem Biophys Res Commun. 2007;361(4):865-869. (Pubitemid 47263454)
43. Vogler M, Butterworth M, Majid A, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces ∼1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2008;113(18):4403-4413.
44. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006;8:1419-1421. (Pubitemid 44057478)
45. Whitecross KF, Alsop AE, Cluse LA, et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009;113(9):1982-1991.
46. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell. 1991;67:889-899. (Pubitemid 121001503)
47. Motoyama N, Wang FP, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science. 1995;267:1506-1510.
48. Kelly PN, White MJ, Goschnick MW, et al. Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ. 2010;17(10):1655-1664.
49. Tu Y, Renner S, Xu F-H, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58(2):256-262. (Pubitemid 28047064)
50. Oakes SR, Vaillant F, Lim E, et al. Breast Cancer Special Feature: Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A. 2012;109(8):2766-2771.